NCT07020949View on ClinicalTrials.gov

Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of THDBH120 in Chinese Patients With T2DM

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

June 13, 2024

Primary Completion Date

November 27, 2024

Study Completion Date

November 27, 2024

Conditions

Diabetes Mellitus Type 2

Interventions

DRUG

THDBH120 injection

Participants received THDBH120 by subcutaneous injection.

DRUG

Placebo of THDBH120 injection

Participants received placebo by subcutaneous injection.

Trial Locations (1)

Unknown

Peking University First Hospital, Beijing

All Listed Sponsors

lead

Tonghua Dongbao Pharmaceutical Co.,Ltd

INDUSTRY

NCT07020949 - Multiple Dose Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Efficacy of THDBH120 in Chinese Patients With T2DM | Biotech Hunter | Biotech Hunter